What You'll Learn
Table of Contents
What The Discontinuation Data Shows
Start with the number rather than the reassurance:
Pooling randomised trials, non-randomised studies and observational data on discontinuation, mean regain was 2.20 kg for liraglutide and 9.69 kg for semaglutide or tirzepatide — larger in absolute terms for the drugs that produced the larger initial loss.
PubMed PMID: 41938838 ↗Bottom line: Larger initial losses came with larger absolute regain. That is not a reason to avoid the medication — it is a reason to treat the end of treatment as a planned transition rather than an event that happens to you.
Legion Whey+
Muscle is what holds resting metabolic rate up, and protein plus lifting is what holds muscle. This is the same lever as during treatment, just for longer.
Check price at Legion →Disclosure: we earn a commission if you buy through this link, at no extra cost to you. It does not change what this page says. Supplements do not treat or replace a GLP-1 medication, and nothing here is medical advice.
Why It Comes Back
Nothing about losing weight removes the biology that defended it.
After weight loss, appetite signalling pushes upward and energy expenditure sits somewhat lower than body size alone predicts. These medications work by opposing the first half of that. Remove the drug and the opposition goes with it, while the underlying pressure remains.
The trial extension data makes the point plainly:
Following the original STEP-1 population after semaglutide was stopped, participants regained weight and the cardiometabolic improvements accrued during treatment reversed toward baseline.
Full study on PMC ↗Why Clinicians Call It Recurrence, Not Failure
The framing matters more than it sounds.
Nobody describes blood pressure returning after stopping an antihypertensive as a personal failure. It is what happens when you stop treating a chronic condition. Obesity is increasingly managed the same way, and weight returning after discontinuation is the same phenomenon.
This is not an excuse. It is the correct model, and it changes what questions you ask — from “why did I fail?” to “what is the plan for the maintenance phase?”
The Variable You Influenced Months Ago
Regain is not fixed in size, and the largest thing you influence is what you lost in the first place.
Lean mass is metabolically active. Someone who protected it through the loss phase arrives at maintenance with higher energy expenditure than someone who lost the same weight with more of it coming from muscle — the second person has to eat less to hold the same weight, permanently.
Fat mass fell 14% at month 7 and 18% at month 12. Lean mass dropped initially (−3 kg at month 7) then stabilised rather than continuing to fall. Handgrip strength improved by 4.5 kg at month 12, and sarcopenic obesity prevalence fell from 49% at baseline to 33%.
Full study on PMC ↗Bottom line: Lean mass fell early then stabilised in that cohort, and grip strength improved. The maintenance phase starts being decided in month three of the loss phase, not on the day the prescription ends.
What Actually Helps
The evidence base for maintenance specifically is thinner than for loss. What has support:
- Keep training. The one-year randomised trial that tested exercise alongside a GLP-1 found the combination produced roughly double the body-fat improvement of either alone — and the exercise arm is the part that does not require a prescription.
- Keep protein high. Satiety and lean mass both depend on it, and intake habitually drifts down once appetite returns.
- Do not stop abruptly if you can avoid it. Tapering is a prescriber conversation, but an abrupt end means appetite returns all at once against habits that have not been tested without the drug.
- Keep weighing. Catching 3 kg is a different problem from catching 15 kg.
195 adults completed a low-calorie diet then spent a year randomised to supervised exercise, liraglutide, both, or placebo. Weight change versus placebo was −9.5 kg for the combination, −6.8 kg for liraglutide alone and −4.1 kg for exercise alone. Body-fat percentage fell 3.9 points with the combination — roughly double exercise (1.7) or liraglutide (1.9) on their own.
PubMed PMID: 33951361 ↗The Option People Avoid Discussing
For many people the honest answer is continued treatment, at the full dose or a lower maintenance one.
This gets avoided because of a lingering sense that needing medication long-term is a failure of willpower. Applied to any other chronic condition that reasoning would be obviously wrong.
Cost, access and tolerability are all real constraints, and for some people stopping is the only option. But if the only reason to stop is that stopping feels like the goal, that is worth examining — and worth raising with the prescriber rather than deciding alone.
Important: Do not stop, taper or restart a prescription on your own judgement. Maintenance dosing is a clinical decision and the right answer differs between people.
